Loading page
Loading page
Loading substance route
Dosage data for 4-MeO-PCP carries significant uncertainty; some reports attributed to this substance may represent misidentified compounds. Individual sensitivity varies substantially. Dose-response curves are inconsistent across users.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use can be moderately addictive with high potential for abuse and is capable of causing psychological dependence among certain users. Cravings may occur if usage is suddenly stopped.
Withdrawal effects have been reported upon cessation of chronic use, though specific physical withdrawal symptoms are not well characterized due to limited research history.
The exact toxic dosage is unknown due to very limited history of human usage. One fatality has been reported in combination with multiple other substances (4-HO-MET, venlafaxine, olanzapine, lorazepam, and hydroxyzine).
Repeated excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency and urgency, pelvic and bladder pain, hematuria, and incontinence; these effects can be avoided by limiting use to less than weekly.
Psychotic episodes, disturbing hallucinations, delusions, anxiety, and paranoia are reported as potential negative effects. Risk of adverse psychological reactions increases with higher doses and redosing.
4-MeO-PCP was originally synthesized in 1965 by Victor Maddox, a medicinal chemist working at the pharmaceutical company Parke-Davis. The compound remained largely obscure for decades following its initial creation.…
Prohibited under Ley 20000 (the Chilean drug control law), which explicitly covers all esters and ethers of phencyclidine. As 4-MeO-PCP is an ether of PCP, it falls under this provision.
Sweden's public health agency recommended classifying 4-MeO-PCP as a hazardous substance on November 10, 2014.
Classified as a controlled drug under national legislation. Possession, production, supply, and importation are prohibited.
Not federally scheduled, but may be prosecuted as a PCP analogue under the Federal Analogue Act when sold for human consumption or possessed with intent to ingest. The DEA has indicated it considers structurally similar recreational drugs to be controlled substance analogues. Virginia temporarily classified it as Schedule I from June 26, 2019 through December 25, 2020.
Controlled substance under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since September 27, 2021. Production, distribution, and possession with intent to supply are prohibited.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause added by S.I. 2013/239, which came into effect on February 26, 2013. This clause encompasses derivatives of 1-phenylcyclohexylamine where the amine has been replaced with a piperidyl group and further substituted in the phenyl ring with an alkoxy substituent. Possession, production, supply, and importation are prohibited.
11 sources cited